Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Feature|Articles|September 23, 2026
Shaping the Future of Market Access: Q&A with Jen Norton
Author(s)Jen Norton
Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Advertisement
Advertisement
How to help drug manufacturers navigate complex market factors to reach more patients is a challenge nearly every company faces. That’s why market access strategies continue to be top of mind in the industry. Recently, Pharmaceutical Executive caught up with Jen Norton, a veteran in market access who recently joined EVERSANA.
Related to this article
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Advertisement
Advertisement